Derek T Chalmers
CIK 1166287 · President & CEO · last filed 2021-09-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CARA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1 PARROTT DRIVE
SHELTON, CT 06484
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Tvardi Therapeutics, Inc. (CARA) Delisted | President & CEO | 27,539 | $15.96 | $439.5K | -$7.20M | 49 | 2021-09-09 |
Recent Filings · Page 3 of 5
49 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-12-04 | Tvardi Therapeutics, Inc. (CARA) Delisted | Mixed | −699 | -$440.3K | EDGAR |
| 2019-11-05 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −5,000 | -$104.0K | EDGAR |
| 2019-10-03 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −10,000 | -$182.8K | EDGAR |
| 2019-09-05 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −5,000 | -$116.3K | EDGAR |
| 2019-08-05 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −10,000 | -$232.7K | EDGAR |
| 2019-05-30 | Tvardi Therapeutics, Inc. (CARA) Delisted | Mixed | +14,472 | -$118.4K | EDGAR |
| 2019-03-08 | Tvardi Therapeutics, Inc. (CARA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-03-05 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −9,792 | -$166.9K | EDGAR |
| 2019-02-05 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −20,000 | -$299.8K | EDGAR |
| 2019-01-04 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −20,000 | -$272.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.